Core Viewpoint - The company, Jiaying Pharmaceutical, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact its operations and reputation [1]. Group 1: Company Overview - Jiaying Pharmaceutical specializes in the research, production, and sales of traditional Chinese medicine, holding a significant position in the industry with 58 drug varieties across 5 dosage forms [3]. - The company's leading products, Shuangliao Houfeng San and Zhonggan Ling Pian, have been recognized as national protected traditional Chinese medicine varieties and have won the "Guangdong Province Famous Brand Product" title [3]. - Jiaying Pharmaceutical's subsidiary, Jiaying Hunan, produces unique products listed in the national medical insurance directory, including Jieguzhi Qili Pian and Jieguzhi Qili Jiao Nang, both of which have patent authorization [3]. Group 2: Financial Performance - In 2024, Jiaying Pharmaceutical reported total revenue of 376 million yuan, a year-on-year decline of 29.46%, and a net profit attributable to shareholders of 20.61 million yuan, down 39.94% [3]. - Despite the financial challenges, the company has implemented measures such as optimizing production processes and enhancing cost control to maintain stable core business operations [3]. - In Q1 2025, Jiaying Pharmaceutical achieved revenue of 122 million yuan, a year-on-year increase of 28.83%, primarily due to expanded sales channels [3]. - The net profit attributable to shareholders for the same period was 15.40 million yuan, reflecting a significant year-on-year growth of 197.23%, driven by successful partnerships with major retail chains and improved cost management [3]. Group 3: Corporate Governance - During a recent earnings briefing, the company addressed investor concerns regarding its governance, stating that the current Secretary of the Board was recruited from a state-owned enterprise, emphasizing high compliance management standards [4]. - The company has undertaken substantial efforts in compliance and internal control, including appointing dedicated compliance personnel and implementing electronic process management [4]. - Future plans include enhancing compliance systems and culture, ensuring business operations and information disclosures are compliant and scientifically managed [4].

Group 1 - Jia Ying Pharmaceutical is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, having received a notice of case filing on May 28, 2025 [2] - ST United plans to acquire 100% of Run Tian Industrial through a combination of share issuance and cash payment, with the stock set to resume trading on May 29 [3] - Long Gao Co., Ltd. is undergoing a restructuring of its controlling shareholder, Longyan Investment Development Group, which has established a new investment development group with a registered capital of 3 billion yuan [4] Group 2 - San You Chemical's controlling shareholder intends to inject 100 million yuan into its subsidiary, Tangshan San You Silicon Industry, through a private agreement [5] - ST Ji Pharmaceutical's stock will be delisted on May 29, 2025, due to a continuous closing price below 1 yuan for twenty trading days [6] - Hehe Information plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [8] Group 3 - ST Huaxi has signed a significant contract worth approximately 2.9 billion USD (about 20.84 billion yuan) for a project in Iraq, which represents 80.38% of its latest audited revenue [9] - ST Longjin's stock will enter a delisting preparation period starting June 6, 2025, following a decision by the Shenzhen Stock Exchange [10] - Zhenbao Island's wholly-owned subsidiary intends to acquire a 49% stake in its controlling subsidiary, Guizhou Shennong Valley [11]

Macro Dynamics - The Chinese Foreign Ministry urged the U.S. to ensure the legitimate rights and interests of international students, including Chinese students, amid reports of a halt in student visa issuance [1] - China announced a trial visa exemption policy for Saudi Arabia, Oman, Kuwait, and Bahrain from June 9, 2025, to June 8, 2026, allowing ordinary passport holders from these countries to enter China without a visa for up to 30 days [2] Market Data - From May 1 to 25, the retail sales of passenger cars in China reached 1.358 million units, a year-on-year increase of 16%, with a cumulative retail of 8.23 million units for the year, up 9% [3] - The retail sales of new energy vehicles during the same period were 726,000 units, marking a 31% year-on-year increase, with a penetration rate of 53.5% [3] - From January to April, the total profit of state-owned enterprises was 1.34914 trillion yuan, a year-on-year decrease of 1.7% [4] Company Dynamics - China’s Ministry of Education reported that the number of candidates for the national college entrance examination in 2025 is expected to reach 13.35 million [5] - The first-instance trial of former chairman of Everbright Trust, Yan Guijun, for bribery and abuse of power began, with allegations of illegal loan approvals totaling over 6.39 billion yuan [7] - Stellantis announced Antonio Filosa as the new CEO, effective June 23, 2024, following his extensive experience within the company [15] - Douyin e-commerce plans to reduce freight insurance costs for merchants by 5% to 15% starting June 6, 2024, potentially saving over 1 billion yuan in operating costs for merchants in the coming year [17]

Group 1 - Jia Ying Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, having received a notice of case filing on May 28, 2025 [2] - ST United plans to acquire 100% of Run Tian Industrial through a combination of share issuance and cash payment, aiming to enhance its positioning as a comprehensive service provider in cultural tourism consumption [3] - Long Gao Co., Ltd. announced the restructuring of its controlling shareholder, Longyan Investment Development Group, which has established a new investment development group with a registered capital of 3 billion yuan [4] Group 2 - Sanyou Chemical's controlling shareholder intends to inject 100 million yuan into its subsidiary, Tangshan Sanyou Silicon Industry Co., Ltd., through a private agreement, without affecting the consolidation scope of the company [5] - ST Ji Pharmaceutical's stock will be delisted on May 29, 2025, due to a continuous closing price below 1 yuan for twenty trading days, triggering termination of listing rules [6] - Taiji Industrial plans to repurchase shares worth 100 million to 120 million yuan, with a maximum repurchase price of 10.38 yuan per share [7] Group 3 - China Energy Construction's subsidiary has won a bid for a coal power project worth approximately 14.586 billion yuan, marking a significant contract win [8][9]

关于收到中国证券监督管理委员会立案告知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日收到中 国证券监督管理委员会（以下简称"中国证监会"）的《立案告知书》（证监立案 字 0062025010 号），因公司涉嫌信息披露违法违规，根据《中华人民共和国证券 法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 证券代码：002198 证券简称：嘉应制药 公告编号：2025-033 广东嘉应制药股份有限公司 公司将积极配合中国证监会的相关工作，并严格按照规定及监管要求履行信 息披露义务。公司指定的信息披露媒体为《证券时报》《中国证券报》《证券日报》 和巨潮资讯网（http://www.cninfo.com.cn），公司相关信息均以在上述指定信息披 露媒体登载的公告为准。敬请广大投资者关注公司相关公告，理性投资，注意投 资风险。 特此公告。 广东嘉应制药股份有限公司董事会 2025 年 5 月 29 日 ...

Group 1 - Ningde Times participated in the completion of the Zeyuan Fund, with a total scale of 10.128 billion yuan, increasing by 50.42% from the previous announcement [3] - Zhongjin Gold's controlling shareholder plans to inject four companies into the company to resolve competition issues, including acquiring stakes in Inner Mongolia Jintao and others [4][5] - Keli Yuan plans to invest an additional 500 million yuan in a storage industry fund, increasing its total investment to 700 million yuan [6] Group 2 - China Shenhua intends to acquire 7.43% of the National Energy Group Financial Company for 2.929 billion yuan, which is expected to increase its net profit by 97 million yuan [7] - Weir Shares plans to issue H-shares and list on the Hong Kong Stock Exchange [8] - Hualan Shares is establishing a joint venture for Tibetan medicinal baths and plaster products, with a registered capital of 7 million yuan [15] Group 3 - Yunnan Copper plans to acquire 40% of Liangshan Mining through a share issuance, with the stock resuming trading on May 26 [10] - Ruishun Technology's subsidiary plans to establish a joint venture in Malaysia to provide automation solutions [11] - ST Quanwei's stock will be subject to additional risk warnings due to ongoing litigation involving a subsidiary [12] Group 4 - Hengfeng Information's controlling shareholder has terminated the agreement to transfer part of the company's shares, with no impact on control [13] - Huadian Technology's subsidiary has not yet commenced substantial construction on a polyurethane new materials project [14] - ST Yinjian will remove the delisting risk warning and some other risk warnings, changing its stock name [38] Group 5 - China Tonghao won approximately 3.789 billion yuan in contracts in the rail transit market from March to April [39] - Intercontinental Oil and Gas plans to invest about 848 million USD in the Iraq South Basra project [40][41] - Jiaying Pharmaceutical's subsidiary signed a contract for the development of a traditional Chinese medicine innovation project [42] Group 6 - Ruidong Intelligent signed a strategic cooperation agreement with Shunde Vocational and Technical College to enhance collaboration in technology [43] - Jiaojian Co. won a bid for a drainage project worth 225 million yuan [44] - Hengshun Vinegar's controlling shareholder plans to increase its stake in the company by 50 to 100 million yuan [45]

Group 1 - Zhongjin Gold plans to inject four companies, including Inner Mongolia Jintao, into the company to resolve competition issues, acquiring stakes of 49.34%, 80%, 70%, and 70% respectively [3] - Keli Yuan intends to invest an additional 500 million yuan in a storage industry fund, increasing its total commitment from 200 million yuan to 700 million yuan, holding 49.93% of the fund [4] - China Shenhua plans to acquire a 7.43% stake in the National Energy Group Financial Company for 2.929 billion yuan, which is expected to increase its net profit by 97 million yuan [5] Group 2 - Weier Co. plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders [6] - China Communication Signal plans to invest approximately 3.789 billion yuan in 11 major rail transit projects, accounting for 11.67% of its audited revenue for 2024 [8] - Intercontinental Oil and Gas intends to invest approximately 848 million USD in the Iraq South Basra Integrated Project, with a total investment of about 1.266 billion USD [9] Group 3 - Jiaying Pharmaceutical's subsidiary signed a technology development contract with Hunan University of Chinese Medicine to develop a new traditional Chinese medicine [10] - Ruide Intelligent signed a strategic cooperation agreement with Shunde Vocational and Technical College to enhance collaboration in technology and talent development [11] - Jiaojian Co. and its partners won a bid for a drainage project worth 225 million yuan, with an expected contribution of 101 million yuan to the company's revenue [12] Group 4 - Hengshun Vinegar's controlling shareholder plans to increase its stake in the company by investing between 50 million and 100 million yuan [14] - Changhua Group's shareholder platform intends to reduce its stake by up to 3%, amounting to a maximum of 14.1 million shares [15] Group 5 - Yunzhongma plans to raise no more than 640 million yuan through a private placement to fund projects for producing DTY yarn and high-performance leather base fabric [17]

Agreement Overview - Guangdong Jiaying Pharmaceutical Co., Ltd. signed a technology development contract with Hunan University of Chinese Medicine, establishing a cooperative relationship for the development of a traditional Chinese medicine innovation drug, "Juanbi Lijieqing Granules" [1][2] - The contract does not constitute a related party transaction or a major asset restructuring, thus does not require approval from the shareholders or board of directors [1][2] Contract Details - The contract aims to develop "Juanbi Lijieqing Granules," which is based on a clinically effective formula used for many years [2] - Hunan University of Chinese Medicine will provide the traditional Chinese medicine formula and technical support, while Jiaying Pharmaceutical will conduct all necessary research for new drug registration [2][3] - The project includes pharmacological and toxicological studies, clinical research, and the preparation of registration documents [3][4] Project Responsibilities - Hunan University of Chinese Medicine is responsible for providing the formula and clinical technical support, including clinical positioning and trial design [4] - Jiaying Pharmaceutical will handle the pharmaceutical research, pharmacology, toxicology, and clinical studies necessary for the drug registration [4] Intellectual Property and Profit Sharing - Both parties will jointly apply for patents for any technical achievements resulting from the contract [4] - If the technology is successfully commercialized, profits will be shared based on market valuation or through preferential purchasing by Jiaying Pharmaceutical [4] Impact on the Company - The collaboration is expected to enrich the existing research pipeline and enhance research efficiency, aligning with the company's long-term development strategy and benefiting shareholders [5]

证券代码：002198 证券简称：嘉应制药 公告编号：2025-032 广东嘉应制药股份有限公司 关于子公司签署《技术开发合同》的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 近日，广东嘉应制药股份有限公司（以下简称"公司"）全资子公司嘉应制药 （湖南）有限公司（以下简称"子公司"或"乙方"）与湖南中医药大学（以下简称 "甲方"）签署《技术开发合同》。 根据《深圳证券交易所股票上市规则》《公司章程》等相关规定，本次合同 的签署不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重 大资产重组，无需提交股东会和董事会审议。 二、合同签署概况 单位名称：湖南中医药大学 法定代表人：易刚强 注册资本：198,931 万元 注册地址：长沙市岳麓区含浦科教产业园学士路 300 号 宗旨和业务范围：培养高等学历医药人才，促进卫生事业发展。 中医药学 科大专、本科、研究生、硕士研究生、博士研究生学历教育、博士后培养相关科 学研究、继续教育、专业培训、学术交流相关社会服务。 本次签署的《技术开发合同》确立了双方的合作关系，具体实施进 ...

广东嘉应制药股份有限公司 证券代码：002198 证券简称：嘉应制药 公告编号：2025-031 截至本公告披露日，史俊平先生未持有公司股票，公司及公司董事会对史俊 平先生任职财务总监期间为公司发展所做的贡献表示衷心感谢！公司将按照相关 规定尽快完成财务总监的选聘工作，并及时履行信息披露义务。 特此公告。 广东嘉应制药股份有限公司董事会 2025 年 5 月 20 日 关于公司财务总监辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）董事会于近日收到公司财务 总监史俊平先生提交的书面辞职报告。史俊平先生因个人原因辞去公司财务总监 职务，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》《公司章程》等相关规定，其辞职报 告自送达董事会之日起生效，辞任后不再担任公司任何职务，也不会影响公司的 正常运行。 ...